United States Biologics Market Size, Share, Leading Companies, Industry Trends and Forecast by 2032

Comments ยท 8 Views

The increasing prevalence of chronic diseases, including cancer, diabetes, and autoimmune disorders, is propelling the demand for advanced biologic therapies. Major urban centers, such as New York, Chicago, and Los Angeles, are witnessing heightened adoption of biologics due to the concent

United States Biologics Market Overview

Base Year: 2024

Historical Years: 2019-2024

Forecast Years: 2025-2033

Market Growth Rate: 7.4% (2025-2033)

Market Size in 2024: USD 190.3 Billion

Market Forecast in 2033: USD 371.0 Billion

According to the latest report by IMARC Group, the United States biologics market size was valued at USD 190.3 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 371.0 Billion by 2033, exhibiting a CAGR of 7.4% from 2025-2033. The market is experiencing robust growth, driven by expanding healthcare needs and demographic shifts. 

The increasing prevalence of chronic diseases, including cancer, diabetes, and autoimmune disorders, is propelling the demand for advanced biologic therapies. Major urban centers, such as New York, Chicago, and Los Angeles, are witnessing heightened adoption of biologics due to the concentration of specialized healthcare facilities and research institutions. The rising focus on personalized medicine and targeted therapies is further encouraging investment in biologics research and development (R&D). Additionally, biopharmaceutical companies are actively expanding their product pipelines to address a growing range of medical conditions, from rare diseases to widespread chronic illnesses. Collaborations between biotechnology firms and research institutions are driving innovation, leading to the development of cutting-edge biologics, including monoclonal antibodies, gene therapies, and vaccines. Moreover, the increasing availability of biosimilars is making biologic treatments more accessible, contributing to industry expansion while reducing healthcare costs. The expansion of manufacturing capabilities, supported by investments in biopharmaceutical production facilities, is also helping to meet the rising demand for biologics.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/united-states-biologics-market/requestsample

United States Biologics Industry Trends and Drivers:

Key trends in the United States biologics market include technological advancements and the shift toward precision medicine. Innovations in genetic engineering, cell culture technologies, and bioprocessing are enabling the production of highly effective biologics with fewer side effects. The integration of artificial intelligence (AI) and machine learning (ML) in biologics development is improving efficiency and expediting the identification of novel drug targets. The use of advanced delivery systems, such as prefilled syringes and autoinjectors, is further enhancing patient convenience and treatment adherence. Moreover, the rise of advanced biologic therapies for rare and orphan diseases is expanding the market scope, offering new hope for patients with limited treatment options. The increasing focus on oncology biologics, supported by robust clinical trial pipelines, is also driving the development of innovative cancer therapies. The growing number of FDA-approved biologics is further facilitating industry expansion as more effective treatment options become available. Additionally, sustainability is emerging as a significant trend in the biologics market, with manufacturers adopting eco-friendly production processes and biodegradable packaging solutions. The growing emphasis on patient-centric care is driving the adoption of home-administered biologics, reducing the burden on healthcare facilities while improving patient outcomes. Furthermore, investments in cold chain logistics are ensuring the safe and effective distribution of temperature-sensitive biologics across the country, supporting industry expansion.

United States Biologics Industry Segmentation:

The report has segmented the market into the following categories:

Source Insights:

  • Microbial
  • Mammalian
  • Others

Product Insights:

  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Proteins
  • Antisense, RNAi and Molecular Therapy
  • Others

Disease Insights:

  • Oncology
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others

Manufacturing Insights:

  • Outsourced
  • In-House

Regional Insights:

  • Northeast
  • Midwest
  • South
  • West

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Ask Our Expert & Browse Full Report with TOC & List of Figure: https://www.imarcgroup.com/request?type=report&id=20441&flag=C

Key highlights of the Report:

  • Market Performance (2019-2024)
  • Market Outlook (2025-2033)
  • COVID-19 Impact on the Market
  • Porter’s Five Forces Analysis
  • Strategic Recommendations
  • Historical, Current and Future Market Trends
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Structure of the Market
  • Value Chain Analysis
  • Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:  

IMARC Group 

134 N 4th St. Brooklyn, NY 11249, USA 

Email: [email protected] 

Tel No:(D) +91 120 433 0800 

United States: +1-631-791-1145

 

 

 

 

 

Comments